NCT04147858

Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 310 (actual)
• Sponsor: Aptinyx · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of NYX-2925 versus placebo for the treatment of fibromyalgia.

Detailed description

This is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NYX-2925 in subjects with fibromyalgia. This 13- to 16-week study will include a 1- to 4-week Screening Period followed by a 12-week double-blind, randomized, placebo-controlled Treatment Period.

Conditions

• Fibromyalgia

Interventions

Type	Name	Description
DRUG	NYX-2925	NYX-2925 administered orally
DRUG	Placebo	Placebo administered orally

Timeline

• Start date: 2019-11-12
• Primary completion: 2022-06-16
• Completion: 2022-06-16
• First posted: 2019-11-01
• Last updated: 2023-04-28
• Results posted: 2023-04-28

Locations

42 sites across 1 country: United States

Regulatory

• FDA-regulated drug study